A prespecified analysis of the DELIVER clinical trial shows that the sodium/glucose cotransporter 2 inhibitor dapagliflozin benefits patients categorized as having heart failure with improved ejection fraction, a class of patients at high risk of cardiac events but for which limited treatment data are available.
- Orly Vardeny
- James C. Fang
- Scott D. Solomon
